Mesothelioma is a hard cancer to treat that has low survival rates. This makes it a problem for doctors and researchers. A new study is looking to change this by looking at the collagen receptor uPARAP. The current clinical trial is looking at uPARAP, a protein that is found in[…]
Novel Treatments & Drugs
3D Printing and Optical Scanning Can Improve Mesothelioma Treatment
New treatments and technologies offer hope for mesothelioma patients. One technology, 3D printing and optical scanning, has the potential to help those suffering with mesothelioma. The technologies refine and enhance what is known as photodynamic therapy, a promising new approach for the management of mesothelioma. Photodynamic therapy is a unique[…]
ADI-PEG20 Improves Survival in Mesothelioma Patients
ADI-PEG20 is showing promising results for mesothelioma. It is the first treatment to be fully incorporated with chemotherapy in 20 years. The drug will bring hope to thousands of mesothelioma survivors and their families. The drug works by blocking a cancer’s food supply, preventing the spread of the cancer. It[…]
Galinpepimut-S Alongside Opdivo Improves Survival in Mesothelioma Patients
Sellas Life Sciences recently reported results from its Phase I clinical trial showing that survival was improved in pleural mesothelioma patients due to its treatment. The trial looked at the treatment called galinpepimut-S (GPS), an immunotherapy vaccine. There were 10 patients in the study with relapsed or refractory mesothelioma. Nine[…]
Altered CAR-T Cell Therapy for the Treatment of Mesothelioma
Immunotherapy is an innovative and groundbreaking way to treat cancer. It uses the immune system to fight and kill cancer cells. One immunotherapy treatment that is showing good results for certain cancers is called CAR-T cell therapy, which is able to target specific proteins on cancer cells. One of the[…]
ADI-PEG 20 is Being Tested on Non-Epithelioid Mesothelioma
Polaris Group recently announced an application for a rolling submission of a new mesothelioma treatment. The Biologic License Application is the first step in becoming approved by the Food and Drug Administration. The treatment, known as ADI-PEG 20, is for the use on non-epithelioid mesothelioma patients alongside pemetrexed and platinum[…]
A New Biomarker Could Help Doctors Diagnose Mesothelioma
A new biomarker has been found for the diagnosis of mesothelioma by scientists in Japan. Information from this research could revolutionize how mesothelioma is diagnosed and treated in the future. Mesothelioma is a hard cancer to diagnose because it shares symptoms with other cancers. Cancers it can look like include[…]
Chemoimmunotherapy Benefits Pleural Mesothelioma Patients
Results from a phase 3 clinical trial were recently published in the Journal of Clinical Oncology showing that a combination of chemotherapy and immunotherapy for mesothelioma improves patients’ survival more than chemotherapy alone. Researchers combined Keytruda, or pembrolizumab, with platinum and pemetrexed chemotherapy. The overall response rate for patients receiving[…]
Orphan Drug Status Given to New Treatment for Mesothelioma
A new treatment for mesothelioma was recently given orphan drug status by the United States FDA. The company given orphan drug status is known as Avenge Bio, which is a biotechnology company working to create a new immunotherapy treatment regimen. It announced that it was given orphan drug status back[…]
Galinpepimut-S and Nivolumab are Effective and Safe for Mesothelioma
The combination of galinpepimut-S and nivolumab is showing promising results for mesothelioma. The study looked at patients who were refractory or relapsed after at least one standard treatment. The combination met safety and efficacy standards for treatment, leading to a completed phase one trial. The median overall survival, which was[…]
